In a content we shared with you a while ago, we mentioned that the world’s first COVID-19 drug developed by Merck was submitted for emergency use approval. Now there has been an important development on this issue. A special committee of completely independent experts advised that the benefit of the drug outweighs the harm, so approval should be given. All eyes are on the final decision to be made by the US Federal Food and Drug Administration (FDA). . .
Scientists who have completed their work on the drug called molnupiravir recommend this drug, especially for the elderly who have mild to moderate COVID-19, and people with diseases such as diabetes. The drug, which is understood to be unsuitable for pregnant women, is not recommended for vaccinated people who are not covered by clinical trials.
It is also thought to be effective for the variant named Omicron.
Independent scientists, in their voting, came to a decision with 13 to 10. So, most experts argued that this drug should be approved and made available.
Merck officials, who made statements about molnupiravir, based on previous data; They think that the drug will also be effective for the variant named omicron. However, there is not enough data on this subject. As a result of clinical studies, the drug, which reduced the hospitalization and death rate by 30 percent (previously declared to be 50 percent), seems to allow us to enter a new crossroad in the COVID-19 epidemic.
57030
